|1.||Hutt, Evelyn: 6 articles (12/2011 - 10/2004)|
|2.||Liebrecht, Debra: 5 articles (12/2011 - 11/2006)|
|3.||Radcliff, Tiffany A: 5 articles (12/2011 - 11/2006)|
|4.||El-Solh, Ali A: 5 articles (05/2011 - 03/2010)|
|5.||Fish, Ron: 4 articles (12/2011 - 10/2008)|
|6.||Ruscin, J Mark: 4 articles (12/2011 - 11/2006)|
|7.||McNulty, Monica: 3 articles (12/2011 - 10/2008)|
|8.||Drinka, Paul: 3 articles (05/2011 - 12/2010)|
|9.||Kramer, Andrew M: 3 articles (10/2008 - 10/2004)|
|10.||Mylotte, Joseph M: 3 articles (08/2007 - 11/2002)|
01/01/2014 - "In vivo, injection of nHAP in transplanted tumor results in significant reduction (about 50%) of tumor size. "
01/01/2014 - "These results strongly suggest that nHAP can inhibit cancer cell proliferation and have a potential application in cancer treatment. "
01/01/2014 - "The anticancer effect of nHAP is mainly attributed to high amount by endocytosis in cancer cells and inhibition on protein synthesis in cells. "
01/01/2014 - "This paper demonstrates that HAP nanoparticle (nHAP) possesses the ability for inhibiting cancer cell growth in vitro and in vivo. "
03/01/2013 - "Moreover, 50% of cell death was observed at 24 h incubation with nHAp material treated at 200 degrees C @ 5 h cells and 56% cell death at 48 h incubation and hence alters and disturbs the growth of cancer cells. "
|2.||Hepatocellular Carcinoma (Hepatoma)
07/01/2012 - "Following dosage and ratio optimization, polypolex formed by surface modified nHAP and p53 expressing plasmid was applied in vitro for human hepatoma HePG2 cell, and then in vivo for rabbit hepatic VX2 tumour by injection of polypolex/lipodoil emulsion to the hepatic artery in a tumour-target manner. "
04/01/2010 - "The chemicals acted synergistically with rmhTNF-alpha and nHAP in suppressing the growth of hepatoma cells and inducing apoptosis of the cells, with the MDR phenotype reversed, as measured by intracellular ADM retention. "
07/01/2012 - "Based on former discoveries of good liver cell compatibility, safety and tumour-specific inhibition of hydroxyapatite nanoparticles (nHAP), this work tries to make nHAP serve as gene vector in the hepatoma-targeted trans-arterial embolization (TAE) gene therapy to elevate and synergize the therapeutic efficacy of TAE and target gene therapy. "
01/01/2015 - "More studies supported the Pneumonia Severity Index (PSI) as a superior predictor of NHAP severity. "
07/01/2014 - "The aim of this study was to characterize the incidence, microbiology, and outcomes for hospitalized patients with community-acquired pneumonia (CAP) and NHAP. "
01/01/2006 - "Many other studies, however, have considered NHAP as part of the community-acquired pneumonia category. "
09/01/2015 - "However, higher in-hospital mortality in those with NHAP seemed to be related to the PSI score reflecting host factors and severity of pneumonia rather than the type of pneumonia or the presence of drug-resistant pathogens."
09/01/2015 - "Elderly patients admitted with NHAP showed more severe pneumonia at onset, higher rates of potentially drug-resistant pathogens, and worse clinical outcomes than those with CAP. "
04/01/2010 - "CAP empirical antibiotic coverage is still indicated in NHAP, although specific risk factors for multidrug-resistant infections should be assessed on an individual basis."
05/01/1996 - "Pneumoniae infection in CAP and NHAP in this age group. "
10/01/2012 - "Viral infection accounted for more than half (55.9%) of NHAP, whereas bacterial infection was the most frequent (69.9%) cause of CAP. "
02/01/2013 - "This study aimed to investigate the prevalence and clinical characteristics of AP infections and review the need for empirical antibiotics with atypical coverage in NHAP. "
07/15/2011 - "Hence, apart from the issue of the rapid synthesis of nHAp without surfactants or modifiers, the simultaneous and controlled release of dual drugs from nHAp would be a simple, non-toxic and cost-effective method to treat bone infections."
|5.||Human Influenza (Influenza)
10/01/2008 - "A prospective, chart-review study was conducted among residents of 16 NHs in three states with > or = 2 signs and symptoms of NHAP during the 2004--2005 influenza season. "
08/01/2007 - "Pneumococcal and influenza vaccination remain the most important methods for prevention of NHAP at present."
05/01/2005 - "Prevention of CAP and NHAP relies on the combined use of influenza and pneumococcal vaccination, which decreases hospital admissions and in-hospital mortality for CAP. "
06/01/2010 - "Determine whether a comprehensive approach to implementing national consensus guidelines for nursing home acquired pneumonia (NHAP), including influenza and pneumococcal vaccination, improves resident subject and staff vaccination rates. "
05/01/1996 - "To document the prevalence of Legionella sp., Mycoplasma Pneumoniae and Influenza A and B in older patients hospitalized for community-acquired pneumonia (CAP) of nursing-home acquired pneumonia (NHAP) and to determine risk factors associated with fatal outcome or prolonged hospital stay. "
|2.||Anti-Bacterial Agents (Antibiotics)
|6.||Atrial Natriuretic Factor (ANF)
|8.||Proliferating Cell Nuclear Antigen (PCNA)
|10.||Surface-Active Agents (Surfactants)
|1.||Home Nursing (Nursing, Home)
|3.||Artificial Respiration (Mechanical Ventilation)
|4.||Resuscitation Orders (Do Not Resuscitate Orders)
|5.||Oral Hygiene (Dental Hygiene)